EMINE GOKNUR ISIK

Dr. EMINE GOKNUR ISIK

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2021 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
EIEMINE GOKNUR ISIK
EMINE GOKNUR ISIK
DHDuygu Has-Simsek
Duygu Has-Simsek
OSOner Sanli
Oner Sanli
YSYasemin Sanli
Yasemin Sanli
SKSerkan Kuyumcu
Serkan Kuyumcu
Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent 18F-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using 68Ga-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.

19 July 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
SKSerkan Kuyumcu
Serkan Kuyumcu
DDDilara Denizmen
Dilara Denizmen
DSDuygu Has Simsek
Duygu Has Simsek
APArzu Poyanli
Arzu Poyanli
AUAyşe Kubat Uzum
Ayşe Kubat Uzum
YSYasemin Sanli
Yasemin Sanli
Introduction: This study aims to assess 68Ga-Trivehexin PET/CT for detecting hyperfunctioning parathyroid tissue in comparison to [99mTc]Tc-MIBI scintigraphy-SPECT/CT (MIBI scan) in patients with primary hyperparathyroidism (PHPT). Methods: The cohort comprised 13 patients diagnosed with PHPT based on biochemical analyses, including serum calcium, phosphorus, and parathyroid hormone (PTH) levels. Each participant underwent cervical ultrasonography, MIBI scan, and 68Ga-Trivehexin PET/CT imaging. Complementary 4D-CT and [18F]fluorocholine PET/CT were conducted in 7 patients. Ten lesions of 7 patients underwent PTH wash-out (WO) procedure. 68Ga-Trivehexin PET/CT findings were compared with other modalities and PTH-WO results. Results: Ten patients had sporadic PHPT, while 3 were diagnosed with MEN-1 syndrome-associated PHPT. One patient did not have any identifiable parathyroid lesion across the imaging modalities. On a patient-based analysis, MIBI scan and 68Ga-Trivehexin PET/CT identified parathyroid lesions in 10 and 11 patients, respectively. However, 68Ga-Trivehexin PET/CT detected 7 additional parathyroid lesions that were negative on the MIBI scan. Consequently, 17 lesions were identified and confirmed as hyperfunctioning parathyroid tissue through imaging, PTH-WO, or a combination of both modalities. In lesion-based evaluation, 68Ga-Trivehexin identified 16 lesions compared to 10 by MIBI scan, resulting in a detection rate of 94.1% and 58.8%, respectively. Notably, in three patients who underwent [18F]fluorocholine PET/CT, no lesions were detected; yet 68Ga-Trivehexin PET/CT successfully identified parathyroid lesions in two of these patients. Conclusion: Our study provides the first evidence that 68Ga-Trivehexin PET/CT can effectively identify hyperfunctioning parathyroid tissue with a high detection rate warranting further investigations to comprehensively explore its potential in PHPT management.

7 October 2023 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
CCCaner Civan
Caner Civan
SKSerkan Kuyumcu
Serkan Kuyumcu
DSDuygu Has Simsek
Duygu Has Simsek
OSOner Sanli
Oner Sanli
EIEMINE GOKNUR ISIK
EMINE GOKNUR ISIK
YSYasemin Sanli
Yasemin Sanli

30 March 2021 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
DSDuygu Has Simsek
Duygu Has Simsek
SKSerkan Kuyumcu
Serkan Kuyumcu
SKSeyfullah Karadogan
Seyfullah Karadogan
MOMelis Oflas
Melis Oflas
EIEMINE GOKNUR ISIK
EMINE GOKNUR ISIK
YSYasemin Sanli
Yasemin Sanli

10 November 2023 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
DSDuygu Has Simsek
Duygu Has Simsek
YGYunus Guzel
Yunus Guzel
DDDilara Denizmen
Dilara Denizmen
YSYasemin Sanli
Yasemin Sanli
FBFikret Buyukkaya
Fikret Buyukkaya
SKSerkan Kuyumcu
Serkan Kuyumcu

19 November 2024 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
EIEMINE GOKNUR ISIK
EMINE GOKNUR ISIK
DSDuygu Has Simsek
Duygu Has Simsek
NGNurdan Gul
Nurdan Gul
SESukru Mehmet Erturk
Sukru Mehmet Erturk
FBFikret Buyukkaya
Fikret Buyukkaya
SKSerkan Kuyumcu
Serkan Kuyumcu
Purpose: We aimed to compare the diagnostic performance of 68Ga-FAPI-04 (FAPI) in comparison to 68Ga-DOTATATE (SSTR) PET/CT for patients presenting with recurrent medullary thyroid carcinoma (MTC). Patients and Methods: Sixteen MTC patients with elevated calcitonin levels (>150 pg/mL) underwent FAPI and SSTR PET/CT. Two nuclear medicine physicians evaluated all images, categorizing lesions into locoregional metastases, mediastinal lymph nodes (LNs), liver, and bone metastases. SUVmax and tumor-to-background ratio were recorded. PET modalities were compared using the McNemar test. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FAPI and SSTR PET were calculated. Results: The cohort comprised 16 patients (50% female; mean age 50 ± 17 years). Median calcitonin and CEA levels were 6234 pg/mL and 17.3 ng/mL, respectively. In patient-based analysis, SSTR exhibited higher diagnostic sensitivity compared with FAPI (88% vs 81%), resulting a statistically significant difference (P = 0.004). Mean SUVmax and tumor-to-background ratio values were 10.3 and 5.35 for FAPI, and 9.7 and 11.9 for SSTR PET, respectively. In lesion-based analyses, FAPI demonstrated higher accuracy than SSTR for cervical LNs (91.9% vs 50%), mediastinal LNs (94.9% vs 54.4%), and liver metastases (57.4% vs 7.3%), respectively. Notably, 31% of patients (n = 5) with FAP-expressing liver lesions showed no uptake on SSTR imaging. MRI confirmed liver metastases in 3 of these patients; however, 2 FAP-expressing lesions were confirmed as hemangiomas. False-positive findings of DOTA primarily included reactive LNs and bone hemangiomas. Conclusions: FAPI PET presents promising outcomes in detecting metastases in recurrent MTC patients. Although its diagnostic performance matches SSTR on a per-patient basis, FAPI PET exhibits superior sensitivity and accuracy in lesion-based analyses, notably for liver and bone metastases.